sur Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Projects Significant Growth for 2025 and 2026
Viromed Medical AG anticipates substantial revenue growth in the coming years, as outlined in its recent forecast. The company predicts an increase in revenue from EUR 1.37 million in 2024 to between EUR 8 million and EUR 10 million by 2025. A significant surge is expected in 2026, with revenues projected to reach approximately EUR 80 million. This growth is aligned with existing partnerships and distribution agreements.
The financial outlook for 2025 is largely supported by operations of the newly acquired Pharmedix GmbH. Viromed anticipates new products like ViroCAP® and PulmoPlas® will further drive growth in 2026. Despite a low revenue in 2024 due to the end of cooperation with terraplasma medical GmbH, 2025 has already seen revenue more than double compared to the previous year's figures.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Viromed Medical AG